*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
"siRNA-based Therapeutics: Challenges and Opportunities"
Anna Borodovsky, PhD
Principal Scientist
Alnylam Pharmaceuticals
The talk will be an overview of the history of siRNA drug development with a focus on the current state of the field. I will also discuss strategies used to deliver siRNAs for different disease applications. Most of the examples will be drawn from Alnylam’s programs covering siRNA delivery to liver as well as extra-hepatic tissues.
Anna Borodovsky is currently a Principal Scientist at Alnylam Pharmaceuticals where she as worked for the past 6 years focusing on various aspects of siRNA delivery. Prior to joining Alnylam she was a staff scientist at the Broad Institute Chemical Biology Program. Anna did her post-doctoral training at BiogenIdec, working on the role of TNF-family members in mouse models of inflammation. She received her PhD from Harvard University in 2002 working on deubiquitinating enzymes and has a BS in Chemistry from Emory University.
The Parker H. Petit Institute hosts special guests and visitors throughout the year. These seminars are open to all faculty and students.
